Bannerbild German Brest Group - Forschung

Overview of congress submissions from 2012

The following submissions were presented at international congresses in 2012 by members of the German Breast Group:

SABCS

Martin M, Loibl S, von Minckwitz G, Morales S, Crespo C, Anton A, Guerrero A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JA, Gil M,Ramos M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba J R: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - First efficacy results from the LEA study. Cancer Res 72 (24 Suppl.): 91s, 2012

Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M: Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72 (24 Suppl.): 95s, 2012

Loibl S, Jackisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B,Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Nekljudova V, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 72 (24 Suppl.): 96s, 2012

Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial. Cancer Res 72 (24 Suppl.): 102s, 2012

Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Erbstoesser E, Loibl S, Denkert C, von Minckwitz G: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort. Cancer Res 72 (24 Suppl.): 33s, 2012

von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer J-U, Costa S-D, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Res 72 (24 Suppl.): 15s, 2012

Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, von Minckwitz G, Denkert C: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. Cancer Res 72 (24 Suppl.): 36s, 2012

Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. Cancer Res 72 (24 Suppl.): 71s, 2012

Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70. Cancer Res 72 (24 Suppl.): 18s, 2012

Linder M, von Minckwitz G, Kamischke A, Rudolwski C, Eggemann H, Nekljudova V, Loibl S: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE). Cancer Res 72 (24 Suppl.): 43s, 2012

Untch M, Jackisch C, Blohmer J-U, Costa S-D, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Kuemmel S, Schneeweiss A, Paepke S, Loibl S, Nekljudova V, von Minckwitz G: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) GBG 69. Cancer Res 72 (24 Suppl.): 67s, 2012

Thomssen C, Kantelhardt EJ, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jaenicke F, von Minckwitz G, Harbeck N: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. Cancer Res 72 (24 Suppl.): 15s, 2012

ESMO

Ataseven B, Blohmer J.U, Denkert C BeGerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G for the GBG and AGO-B Study Groups: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Annals of Oncology Volume 23 (Supplement 9), 117, 2012

Loibl S, De la Haba J, von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Safety Analysis LEA study. Annals of Oncology Volume 23 (Supplement 9), 118, 2012

ASCO

von Minckwitz G, Mueller B, Blohmer J.U, Kaufmann M, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Ruediger T, Erbstoesser E, Loibl S, Denkert C: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol 30, (suppl; abstr 1023), 2012

Huober J, Denkert C, Minckwitz G, Prinzler J, Kronenwett R, Darb-Esfahani S, Mehta K, Sinn B.V, Untch M, Loibl S: Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. J Clin Oncol 30, (suppl; abstr 523), 2012

Maass N, Harbeck N, Mundhenke C, Lerchenmuller C, Barinoff J, Lueck H.J, Ettl J, Aktas B, Kuemmel S, Roesel S, Wagner S, Müller L, Bischoff J, Luebbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, Loibl S, von Minckwitz G: Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. J Clin Oncol 30, (suppl; abstr 556), 2012

Pirvulescu C, Loibl S, von Minckwitz G, Mau C, Blohmer J.U, Dan Costa S, Eidtmann H, Fasching P.A, Gerber B, Untch M: Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 541), 2012

Sinn B.V, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H.J, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 522), 2012

EBCC

Harbeck N, Maass N, Mundhenke C, Lerchenmüller C, Barinoff J, Etti J, Aktas B, Nekljudova V, von Minckwitz, Loibl S: Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study. European Journal of Cancer Vol. 48, Supplement 1, S43, 2012

Loibl S, von Minckwitz G, Kaufmann M: Adjuvant hormone therapy following primary therapy for endometrial cancer Preview. European Journal of Cancer Vol. 38, Supplement 6, 41-43, 2012

von Minckwitz G, Steffen J, Wiest W, Thomssen C, Augustin D, Conrad B, Wesenberg B, Wittenberg M, Loibl S: Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials. European Journal of Cancer Vol. 48, Supplement 1, S52, 2012

Loibl S, Gerber B: Managing adverse effects of treatment – Fertility. European Journal of Cancer Vol. 48, Supplement 1, S101, 2012

Loibl S: Breast Cancer in the Young. European Journal of Cancer Vol. 48, Supplement 1, S45, 2012

Contact

Hilal Gökgöz

Phone: +4961027480-223

Fax: +4961027480-129

E-Mail: Publication@gbg.de

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd